Northwestern scientists optimize chemotherapy by 10,000 times with nanomedicine

Scientists at Northwestern University, in the United States, have developed an optimized version of 5-fluorouracil, a common chemotherapy drug. The change uses nucleic acid beads to incorporate the drug into DNA structures, increasing solubility and precision against cancer cells. Tests in models of acute myeloid leukemia showed 12.5 times greater penetration and up to 20,000 times greater elimination of diseased cells.
The technique prevents damage to healthy tissues, unlike traditional forms of medicine. Results indicate a 59-fold reduction in disease progression in animals. The research was published in the journal ACS Nano.
- The compound penetrates scavenger receptors abundant in leukemia cells.
- Intracellular enzymes release the drug directly to the target.
- Treated mice showed almost complete elimination of cancer cells in the blood and spleen.
Structure of nanomedicine
Researchers incorporated 5-Fu into strands of DNA that form tiny spheres. This configuration solves the low drug dissolution, less than 1% in biological fluids.
The nanostructurefacilitates selective uptake by tumor cells. Tests demonstrated no nausea, fatigue or cardiac toxicity.
Results in animal models
Mice with acute myeloid leukemia received the optimized treatment. Survival was significantly increased compared to control groups.
Cancer cells in the spleen decreased dramatically. There were no changes in healthy organs.
The study compared equivalent doses of conventional 5-Fu. The SNA version surpassed in efficiency without increasing toxicity.
Targeted Action Engine
Leukemia cells express receptors that recognize DNA beads. After internalization, the DNA degrades and releases the drug.
This release occurs only within the target cells. The process minimizes systemic exposure of the medication.
Application of 5-fluorouracil
5-Fu has been used for decades in the treatment of various cancers. Its low solubility requires high administrations, increasing risks.
The reformulation maintains its antitumor potency. Tests quantified cellular destruction 20 thousand times greater.
Next research steps
The team plans experiments in other animal models. Funding will determine advancement to clinical phases.
Seven therapies based on SNAs are already in human trials. Study leader Chad Mirkin directs the International Nanotechnology Institute.
Structural nanomedicine adjusts nanoparticle shapes for precise interactions with the organism. This approach controls biodistribution and drug release at specific targets, reducing adverse effects in oncological treatments.
SNA Technical Details
Nucleic acid spheres consist of DNA chains anchored in nuclei. 5-Fu is chemically bonded to the ribbons.
This bond improves stability in aqueous media. Tumor cells take up the structures via endocytosis.






